Allergic conjunctivitis is one of the most common ophthalmic disorders worldwide, with symptoms resulting from mast cell degranulation and histamine release.

Until recently, most available ocular treatment required twice-daily dosing for the prevention of ocular itching, the hallmark symptom of allergic conjunctivitis.

This pooled analysis of two similarly designed randomized trials comprising a total of 284 subjects combines efficacy and safety findings after treatment with once-daily alcaftadine 0.25% versus olopatadine 0.2% for prevention of ocular itching associated with allergic conjunctivitis.

At 16 hours post treatment instillation, alcaftadine 0.25% ophthalmic solution provided greater relief of ocular itching compared with olopatadine 0.2% ophthalmic solution, with a similar safety profile.

Results support the use of alcaftadine 0.25% for the prevention of itching associated with allergic conjunctivitis.